LENZ Therapeutics Inc’s filing revealed that its Chief Commercial Officer Olsson Shawn unloaded Company’s shares for reported $0.26 million on Nov 17 ’25. In the deal valued at $26.10 per share,10,000 shares were sold. As a result of this transaction, Olsson Shawn now holds 4,733 shares worth roughly $0.14 million.
Then, SHAWN OLSSON bought 40,000 shares, generating $1,024,000 in total proceeds.
Before that, MCCOLLUM JAMES W bought 10,500 shares. LENZ Therapeutics Inc shares valued at $239,278 were divested by the Director at a price of $22.79 per share. As a result of the transaction, MCCOLLUM JAMES W now holds 10,500 shares, worth roughly $0.31 million.
A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in mid March with a ‘”a Buy”‘ rating. Raymond James began covering LENZ with “an Outperform” recommendation on September 27, 2024. H.C. Wainwright started covering the stock on August 12, 2024. It rated LENZ as “a Buy”.
Price Performance Review of LENZ
On Friday, LENZ Therapeutics Inc [NASDAQ:LENZ] saw its stock jump 6.64% to $29.56. Over the last five days, the stock has gained 15.47%. LENZ Therapeutics Inc shares have fallen nearly -14.69% since the year began. Nevertheless, the stocks have risen 2.39% over the past one year. While a 52-week high of $50.40 was reached on 10/02/25, a 52-week low of $16.53 was recorded on 04/09/25.
Levels Of Support And Resistance For LENZ Stock
The 24-hour chart illustrates a support level at 27.92, which if violated will result in even more drops to 26.27. On the upside, there is a resistance level at 30.73. A further resistance level may holdings at 31.89.
How much short interest is there in LENZ Therapeutics Inc?
A steep rise in short interest was recorded in LENZ Therapeutics Inc stocks on 2025-10-31, growing by 1.96 million shares to a total of 7.23 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 5.27 million shares. There was a rise of 27.11%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on April 15, 2024 when William Blair began covering the stock and recommended ‘”an Outperform”‘ rating.
